Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2022-08-05 |
<EvidenceVariable xmlns="http://hl7.org/fhir">
<id value="7751"/>
<meta>
<versionId value="12"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: EvidenceVariable</b><a name="7751"> </a><a name="hc7751"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceEvidenceVariable "7751" Version "12" </p></div><p><b>url</b>: <code>https://fevir.net/resources/EvidenceVariable/7751</code></p><p><b>identifier</b>: FEvIR Object Identifier/7751</p><p><b>version</b>: 1.0.0-ballot</p><p><b>name</b>: Therapeutic_dose_anticoagulation_with_heparin</p><p><b>title</b>: Therapeutic-dose anticoagulation with heparin</p><p><b>status</b>: active</p><p><b>date</b>: 2022-08-05 14:37:53+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.</p><p><b>copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>author</b>: Brian S. Alper: </p><blockquote><p><b>characteristic</b></p><blockquote><p><b>definitionByCombination</b></p><p><b>code</b>: any-of</p><blockquote><p><b>characteristic</b></p><p><b>definitionCodeableConcept</b>: ATTACC investigational arm: Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>timeFromEvent</b></p></blockquote></blockquote><blockquote><p><b>characteristic</b></p><p><b>definitionCodeableConcept</b>: ACTIV-4a investigational arm: Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>timeFromEvent</b></p></blockquote></blockquote><blockquote><p><b>characteristic</b></p><p><b>definitionCodeableConcept</b>: REMAP-CAP investigational arm: Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>timeFromEvent</b></p></blockquote></blockquote></blockquote></blockquote></div>
</text>
<url value="https://fevir.net/resources/EvidenceVariable/7751"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="7751"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<version value="1.0.0-ballot"/>
<name value="Therapeutic_dose_anticoagulation_with_heparin"/>
<title value="Therapeutic-dose anticoagulation with heparin"/>
<status value="active"/>
<date value="2022-08-05T14:37:53.832Z"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<description
value="Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours."/>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<author>
<name value="Brian S. Alper"/>
</author>
<characteristic>
<definitionByCombination>
<code value="any-of"/>
<characteristic>
<definitionCodeableConcept>
<text
value="ATTACC investigational arm: Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
</definitionCodeableConcept>
<timeFromEvent>
<description
value="Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen>24 hours, provided oxygen was required), whichever comes first."/>
<range>
<low>
<value value="0"/>
<unit value="days"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
</high>
</range>
</timeFromEvent>
</characteristic>
<characteristic>
<definitionCodeableConcept>
<text
value="ACTIV-4a investigational arm: Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal."/>
</definitionCodeableConcept>
<timeFromEvent>
<description
value="Up to 14 days or until hospital discharge, whichever comes first."/>
<range>
<low>
<value value="0"/>
<unit value="days"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
</high>
</range>
</timeFromEvent>
</characteristic>
<characteristic>
<definitionCodeableConcept>
<text
value="REMAP-CAP investigational arm: Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
</definitionCodeableConcept>
<timeFromEvent>
<description
value="Up to 14 days or until hospital discharge, whichever comes first."/>
<range>
<low>
<value value="0"/>
<unit value="days"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
</high>
</range>
</timeFromEvent>
</characteristic>
</definitionByCombination>
</characteristic>
</EvidenceVariable>
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2024-05-18
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change